good work... I guess not surprised the withdrawals are slower (sigh)
to the casual observer, seems redundant to have two layers of approvals... if the FDA is assessing efficacy for a drug, then I would think it should be covered for that indication... and vice versa.
good work... I guess not surprised the withdrawals are slower (sigh)
to the casual observer, seems redundant to have two layers of approvals... if the FDA is assessing efficacy for a drug, then I would think it should be covered for that indication... and vice versa.